San Francisco ARCC
UC San Francisco
350 Parnassus Avenue, Suite 905
San Francisco, CA 94143
Website: University of California, San Francisco
Principal Investigator: Bruce L. Miller, M.D.
Medical Director: Bruce L. Miller, M.D.
The University of California, San Francisco (UCSF) Program for Alzheimer's Disease Care and Education (PACE) was established in 1985 as one of six original California Department of Health Services' Alzheimer's Disease Diagnostic and Treatment Centers (ADDTCs). The Center was initially developed in the Department of Psychiatry's Mental Health and Aging division at the Langley Porter Psychiatric Institute (LPPI). The LPPI program has a long history of social science and behavioral investigations that have led to improved understanding of caregiver stress and patient care management across cultures.
In 1999, UCSF became an Alzheimer's Disease Research Center of California (ARCC) with Dr. Bruce Miller as Principal Investigator and Medical Director. Dr. Miller is a Professor of Neurology and Psychiatry at UCSF where he directs the aging and dementia program. Dr. Miller was recruited to UCSF in the fall of 1998 in order to establish a clinical dementia program, and holds the A.W. and Mary Margaret Clausen Distinguished Chair. Since his arrival, Dr. Miller has established strong linkages between existing clinical, research, and basic science programs and community agencies. The UCSF ARCC has been organized to provide outstanding diagnostic and treatment services to individuals with dementia and to their families.
One of the primary focuses of research at UCSF is to learn more about the clinical, genetic, imaging, emotional and diagnostic features of Mild cognitive Impairment (MCI), Alzheimer's disease and non-AD dementias including frontotemporal lobar degeneration (FTLD), Creutzfeldt-Jakob disease (CJD), Cortical Basal Degeneration (CBD), Dementia with Lewy Bodies and Vascular Dementia. The purpose of these studies is to collect longitudinal clinical, imaging, behavioral, and autopsy data to be analyzed with the goal of improving clinical care for patients with these conditions.
In 2003, UCSF was designated as a national Alzheimer's Disease Research Center (ADRC). Funded by the National Institutes of Health, this large collaborative project is composed of multiple institutions and locations. It is designed to integrate basic science and clinical resources in order to investigate the clinical, molecular, neuropathological and neuroimaging features of Alzheimer's disease (AD), non-AD dementias, and mild cognitive impairment (MCI).